Cancer Drug Design and Discovery, 2nd Edition

  • Published By:
  • ISBN-10: 0123972280
  • ISBN-13: 9780123972286
  • DDC: 615.798
  • Grade Level Range: College Freshman - College Senior
  • 640 Pages | eBook
  • Original Copyright 2013 | Published/Released June 2014
  • This publication's content originally published in print form: 2013

  • Price:  Sign in for price



Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA-targeted agents and more. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are now approved for human use and are in the marketplace, as well as those that are still under development. By highlighting some of the general principles involved in taking molecules through basic science to clinical development, this book offers a complete and authoritative reference on the design and discovery of anticancer drugs for translational scientists and clinicians involved in cancer research.

Table of Contents

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
Editor Biography.
1: Basic Principles and Methodlogy.
2: Modern Cancer Drug Discovery.
3: Pharmacogenomics and Personalized Medicines in Cancer Treatment.
4: Natural Product Chemistry and Cancer Drug Discovery.
5: Structural Biology and Anticancer Drug Design.
6: Drugs in the Laboratory and Clinic.
7: Temozolomide: From Cytotoxic to Molecularly Targeted Agent.
8: Temozolomide: Patents and the Perils of Invention.
9: A New Generation of Cell-Targeted Drugs for Cancer Treatment.
10: Inhibition of DNA Repair as a Therapeutic Target.
11: Exploiting Cancer Dependence on Molecular Chaperones: HSP90 Inhibitors Past, Present, and Future.
12: Inhibitors of Tumor Angiogenesis.
13: The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer.
14: Apoptosis in Cancer: Mechanisms, Deregulation, and Therapeutic Targeting.
15: Targeting the MDM2–p53 Protein–Protein Interaction: Design, Discovery, and Development of Novel Anticancer Agents.
16: Targeting Altered Metabolism—Emerging Cancer Therapeutic Strategies.
17: Inhibitors of the Phosphatidylinositol 3-Kinase Pathway.
18: Antibody–Drug Conjugates Delivering DNA Cytotoxics.
19: Inhibition of Telomerase.
20: Targeting B-RAF: The Discovery and Development of B-RAF Inhibitors.
21: The Reality of Cancer Drugs in the Clinic.
22: Failure Modes in Anticancer Drug Discovery and Development.
23: Anticancer Drug Registration and Regulation:Current Challenges and Possible Solutions.
Color Plates.